Acro Biotech

Acro Biotech is a private, commercial-stage diagnostics company focused on manufacturing and distributing rapid lateral flow tests. Its product portfolio targets multiple diagnostic segments, including infectious disease, toxicology, and chronic disease markers, primarily for the international market. The company is developing digital reader technology to enhance its product offerings. Its core strategy leverages experienced leadership and a quality manufacturing foundation to compete in the global point-of-care testing market.

Lateral flow immunoassay (LFIA) for rapid point-of-care testing, with development of digital readers (Lateral Flow Test Reader) and a Fluorescence Immunoassay Analyzer for quantitative, connected diagnostics.

Acro Biotech competes in the crowded global rapid diagnostics market against large, established players like Abbott, Roche, and Siemens Healthineers, as well as numerous specialized lateral flow companies (e.g., QuidelOrtho, BD, Bio-Rad) and low-cost manufacturers. Its differentiation is based on a broad international portfolio, quality manufacturing, and its developing digital ecosystem.